Pfizer today announced that it has formally requested that the Food and Drug Administration amend its COVID-19 vaccine emergency use authorization to allow vaccinations of children between the ages of 5 and 11. FDA plans to discuss the request during an Oct. 26 meeting of its Vaccines and Related Biological Products Advisory Committee. 
 
If FDA’s commissioner accepts a committee recommendation to approve the EUA amendment, the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices will meet to discuss specifics regarding the vaccine’s administration to younger children, including who should be eligible and whether some children should be prioritized. For vaccinations to younger children to begin, ACIP’s recommendations must then be approved by to the CDC director.

Related News Articles

Headline
AHA today participated in a Centers for Disease Control and Prevention Fall Immunization Kick-off Event for partner organizations, which focused on vaccinating…
Headline
As authorized yesterday by the Food and Drug Administration and recommended by its vaccine advisory committee, the Centers for Disease Control and Prevention…
Headline
Under the Department of Health and Human Services’ recent agreement with Regeneron to develop a new monoclonal antibody to prevent COVID-19, the U.S. list…
Headline
In time for back-to-school health screenings, AHA Aug. 25 released an infographic on strategies that clinicians and the Centers for Disease Control and…
Headline
Receiving a COVID-19 mRNA vaccine or booster during pregnancy can benefit pregnant people and their newborn infants, according to findings from a federally…
Chairperson's File
It’s been about 65 years since an effective vaccine was first used worldwide against poliomyelitis, or polio. Until then, polio was responsible for about 500,…